The employer component follows Quebecs mandatory drug coverage model : applied here it would require employer drug plans that already cover obesity-related conditions hypertension, type 2 diabetes, cardiovascular disease to also cover Health Canada-approved GLP-1s for obesity, with no time cap
Mic JA, Rojas-Corrales MO, Gibert-Rahola J, Parellada M, Moreno D, et al
The Restaurant Challenge on GLP-1s Here's what makes restaurants tricky: Portion sizes are 2-3x what you need (most entrees are 800-1,200 calories) Hidden fats everywhere (butter, oil, cream sauces increase nausea risk) Limited protein-forward options (many menus emphasize carbs and fats) Social pressure to "enjoy yourself" (well-meaning friends encouraging you to indulge) Fast pacing (meals arrive quickly, making it easy to eat too fast) Despite these challenges, restaurant eating is absolutely manageable with the right strategies
N-terminal-SNAP-tagged ghrelin receptor (WT or with various mutations) and full-length ghrelin labeled with the dye A2 on an additional cysteine at the C-terminal end of the peptide (ghrelin-A2, synthesized by Vazyme, China) were used as previously described 41
These GLP-1 drugs do not change the fact that our bodies still need a consistent daily intake of important macronutrients and micronutrients like protein, fiber, vitamins and minerals